Lilly agrees to acquire biopharmaceutical firm Versanis for $1.9bn
Lilly intends to bolster outcomes in patients with cardiometabolic conditions through the Versanis takeover. Credit: Jonathan Weiss / Shutterstock.com. Eli Lilly and Company has signed an